214 related articles for article (PubMed ID: 31619730)
1. Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer.
De Clercq K; Xie F; De Wever O; Descamps B; Hoorens A; Vermeulen A; Ceelen W; Vervaet C
Sci Rep; 2019 Oct; 9(1):14881. PubMed ID: 31619730
[TBL] [Abstract][Full Text] [Related]
2. Model-based analysis of treatment effects of paclitaxel microspheres in a microscopic peritoneal carcinomatosis model in mice.
Xie F; De Clercq K; Vervaet C; Van Bocxlaer J; Colin P; Vermeulen A
Pharm Res; 2019 Jun; 36(9):127. PubMed ID: 31236836
[TBL] [Abstract][Full Text] [Related]
3. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
Faria RS; de Lima LI; Bonadio RS; Longo JPF; Roque MC; de Matos Neto JN; Moya SE; de Oliveira MC; Azevedo RB
Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy.
Simón-Gracia L; Hunt H; Scodeller PD; Gaitzsch J; Braun GB; Willmore AM; Ruoslahti E; Battaglia G; Teesalu T
Mol Cancer Ther; 2016 Apr; 15(4):670-9. PubMed ID: 26880267
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel morphological paclitaxel-loaded PLGA microspheres for effective cancer therapy: in vitro and in vivo evaluations.
Zhang Z; Wang X; Li B; Hou Y; Yang J; Yi L
Drug Deliv; 2018 Nov; 25(1):166-177. PubMed ID: 29299936
[TBL] [Abstract][Full Text] [Related]
6. The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model.
Yu J; Lee HJ; Hur K; Kwak MK; Han TS; Kim WH; Song SC; Yanagihara K; Yang HK
Invest New Drugs; 2012 Feb; 30(1):1-7. PubMed ID: 20669041
[TBL] [Abstract][Full Text] [Related]
7. Thermosensitive hydrogel system assembled by PTX-loaded copolymer nanoparticles for sustained intraperitoneal chemotherapy of peritoneal carcinomatosis.
Xu S; Fan H; Yin L; Zhang J; Dong A; Deng L; Tang H
Eur J Pharm Biopharm; 2016 Jul; 104():251-9. PubMed ID: 27185379
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo.
Yao S; Li L; Su XT; Wang K; Lu ZJ; Yuan CZ; Feng JB; Yan S; Kong BH; Song K
J Exp Clin Cancer Res; 2018 Feb; 37(1):29. PubMed ID: 29478415
[TBL] [Abstract][Full Text] [Related]
9. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination.
Emoto S; Yamaguchi H; Kishikawa J; Yamashita H; Ishigami H; Kitayama J
Cancer Sci; 2012 Jul; 103(7):1304-10. PubMed ID: 22429777
[TBL] [Abstract][Full Text] [Related]
11. Genipin-crosslinked gelatin microspheres as a strategy to prevent postsurgical peritoneal adhesions: In vitro and in vivo characterization.
De Clercq K; Schelfhout C; Bracke M; De Wever O; Van Bockstal M; Ceelen W; Remon JP; Vervaet C
Biomaterials; 2016 Jul; 96():33-46. PubMed ID: 27135715
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors.
Bajaj G; Kim MR; Mohammed SI; Yeo Y
J Control Release; 2012 Mar; 158(3):386-92. PubMed ID: 22178261
[TBL] [Abstract][Full Text] [Related]
13. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
[TBL] [Abstract][Full Text] [Related]
14. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Hu H; Lin Z; He B; Dai W; Wang X; Wang J; Zhang X; Zhang H; Zhang Q
J Control Release; 2015 Dec; 220(Pt A):189-200. PubMed ID: 26474677
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy.
Li B; Tan T; Chu W; Zhang Y; Ye Y; Wang S; Qin Y; Tang J; Cao X
Drug Deliv; 2022 Dec; 29(1):75-88. PubMed ID: 34964421
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
Jin X; Mo R; Ding Y; Zheng W; Zhang C
Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
[TBL] [Abstract][Full Text] [Related]
17. Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy.
Dwivedi P; Han S; Mangrio F; Fan R; Dwivedi M; Zhu Z; Huang F; Wu Q; Khatik R; Cohn DE; Si T; Hu S; Sparreboom A; Xu RX
Mater Sci Eng C Mater Biol Appl; 2019 Sep; 102():113-123. PubMed ID: 31146981
[TBL] [Abstract][Full Text] [Related]
18. Programmed 'triple-mode' anti-tumor therapy: Improving peritoneal retention, tumor penetration and activatable drug release properties for effective inhibition of peritoneal carcinomatosis.
Cherukula K; Bae WK; Lee JH; Park IK
Biomaterials; 2018 Jul; 169():45-60. PubMed ID: 29631167
[TBL] [Abstract][Full Text] [Related]
19. Development of paclitaxel loaded pegylated gelatin targeted nanoparticles for improved treatment efficacy in non-small cell lung cancer (NSCLC): an in vitro and in vivo evaluation study.
Gu M; Luan J; Song K; Qiu C; Zhang X; Zhang M
Acta Biochim Pol; 2021 Aug; 68(4):583-591. PubMed ID: 34355554
[TBL] [Abstract][Full Text] [Related]
20. Novel Soluplus(®)-TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines.
Bernabeu E; Gonzalez L; Cagel M; Gergic EP; Moretton MA; Chiappetta DA
Colloids Surf B Biointerfaces; 2016 Apr; 140():403-411. PubMed ID: 26780253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
